A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetics of Empagliflozin and Linagliptin After Coadministration in Healthy Male Volunteers

Clinical Therapeutics

Volumn 35, Issue 1, 2013, Pages

  Friedrich, Christian ^a   Metzmann, Katrin ^a   Rose, Peter ^a   Mattheus, Michaela ^a   Pinnetti, Sabine ^a   Woerle, Hans J ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

diabetes; DPP 4 inhibitor; drug drug interaction; empagliflozin; linagliptin; SGLT2 inhibi tor

Indexed keywords

EMPAGLIFLOZIN; LINAGLIPTIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; HYPOGLYCEMIA; MALE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; STEADY STATE; VOMITING;

EID: 84872418644     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.12.002     Document Type: Article

References (30)

1. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009, 52:17-30.
2. Turner R.C., Cull C.A., Frighi V., Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999, 281:2005-2012.
3. Phung O.J., Scholle J.M., Talwar M., Coleman C.I. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010, 303:1410-1418.
4. Handelsman Y., Mechanick J.I., Blonde L., et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endoc Pract 2011, 17(Suppl 2):1-53.
5. White J.R. Apple trees to sodium glucose co-transporter inhibitors: a review of SGLT2 inhibition. Clin Diabetes 2010, 28:5-10.
6. Salvatore T., Carbonara O., Cozzolino D., et al. Kidney in diabetes: from organ damage target to therapeutic target. Curr Drug Metab 2011, 12:658-666.
7. Abdul-Ghani M.A., Norton L., DeFronzo R.A. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011, 32:515-531.
8. Grempler R., Thomas L., Eckhardt M., et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012, 14:83-90.
9. Port A., Macha S., Seman L., et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of BI10773, a sodium-glucose co-transporter inhibitor (SGLT-2), in healthy volunteers. Diabetes 2010, 59(Suppl 1):A155. [569-P].
10. Seman L., Macha S., Jones P., et al. Safety and tolerability of BI 10773, a sodium-glucose co-transporter (SGLT-2) inhibitor, following 8-days treatment in patients with type 2 diabetes. Diabetes 2010, 59(Suppl 1):A156. [571-P].
11. Ferrannini E., Seman L., Seewaldt-Becker E., et al. The potent and highly selective sodium glucose cotransporter-2 (SGLT-2) inhibitor BI 10773 is safe and efficacious as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2010, 53(Suppl 1):S531. [877].
12. Heise T., Seewaldt-Becker E., Macha S., et al. BI 10773, a sodium-glucose co-transporter inhibitor (SGLT-2), is safe and efficacious following 4-week treatment in patients with type 2 diabetes. Diabetes 2010, 59(Suppl1):A172. [629-P].
13. Rosenstock J., Jelaska A., Seman L., et al. Efficacy and safety of BI 10773, a new sodium glucose cotransporter (SGLT-2) inhibitor, in type 2 diabetes inadequately controlled on metformin. Diabetes 2011, 60(Suppl 1):A271. [989-P].
14. Thomas L., Tadayyon M., Mark M. Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazol in-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models. J Pharmacol Exp Ther 2009, 328:556-563.
15. Tradjenta (linagliptin) prescribing information Boehringer Ingelheim Pharmaceuticals, Inc, Accessed June 1, 2012. http://www.tradjenta.com.
16. Trajenta (linagliptin) summary of product characteristics European Medicines Agency, Accessed June 1, 2012. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002110/human_med_001482.jsp%26mid=WC0b01ac058001d124.
17. Barnett A.H., Harper R., Toorawa R., et al. Linagliptin monotherapy improves glycaemic control in type 2 diabetes patients for whom metformin therapy is inappropriate. Diabetologia 2010, 53(Suppl 1):S327.
18. Taskinen M.R., Rosenstock J., Tamminen I., et al. Efficacy and safety of linagliptin in type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes 2010, 59(Suppl 1):A158.
19. Lewin A.J., Arvay L., Liu D., et al. Safety and efficacy of linagliptin as add-on therapy to a sulphonylurea in inadequately controlled type 2 diabetes. Diabetologia 2010, 53(Suppl 1):S326.
20. Owens D.R., Swallow R., Dugi K.A., Woerle H.J. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med 2011, 28:1352-1361.
21. Macha S., Port A., Dieterich S., et al. BI 10773, a sodium glucose cotransporter inhibitor (SGLT-2), does not alter the pharmacokinetics of metformin following multiple oral administrations in healthy volunteers. Diabetes 2010, 59(Suppl 1):A554. [2112-PO].
22. Graefe-Mody E.U., Padula S., Ring A., et al. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin 2009, 25:1963-1972.
23. Medical Dictionary for Drug Regulatory Activities (MedDRA) 2009, Version 12.0, Maintenance and Support Services Organization, Chantilly, VA. 12th ed.
24. Fuchs H., Binder R., Greischel A. Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats. Biopharm Drug Dispos 2009, 30:229-240.
25. Heise T., Graefe-Mody E.U., Hüttner S., et al. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab 2009, 11:786-794.
26. Huttner S., Graefe-Mody E.U., Withopf B., et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol 2008, 48:1171-1178.
27. Sarashina A., Sesoko S., Nakashima M., et al. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. Clin Ther 2010, 32:1188-1204.
28. Brand T., Macha S., Mattheus M., et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, co-administered with sitagliptin in healthy volunteers. Adv Ther 2012, 29:889-899.
29. Macha S., Mattheus M., Pinnetti S., et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and glimepiride following co-administration in healthy volunteers: A randomised, open-label, crossover study. Diabetes Res Clin Metab 2012, 1:14.
30. Blech S., Ludwig-Schwellinger E., Grafe-Mody E.U., et al. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos 2010, 38:667-678.